人工智能用于神经肿瘤学疗效评估(AI-RANO)第二部分:标准化、验证与良好临床实践的建议
该政策综述提出神经肿瘤学中人工智能(AI)方法标准化与良好临床实践的建议,关注重复性、可重复性和稳定性,讨论标准化与验证路径以实现可信AI并支持下一代临床试验,最后展望AI赋能的神经肿瘤学未来。
要点
- AI在神经肿瘤学疗效评估中的广泛适用与临床转化受泛化性、可重复性、可扩展性和验证问题限制。
- 建议聚焦AI方法在神经肿瘤学中的标准化与良好临床实践,涵盖重复性、可重复性和稳定性。
- 提出标准化与验证路径,以可信AI支持下一代临床试验。
核心结论
- 本政策综述旨在作为医疗保健尤其是神经肿瘤学中AI方法标准化与良好临床实践建议的领先资源。
研究设计与样本
- 政策综述,研究AI在神经肿瘤学疗效评估中的重复性、可重复性和稳定性,以及影响这些计算方法的因素和促进这些目标的公开开源数据与计算软件工具。
主要发现
- AI算法包括影像组学的应用日益增多,但泛化性、可重复性、可扩展性和验证问题限制其广泛适用与临床转化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Technological advancements have enabled the extended investigation, development, and application of computational approaches in various domains, including health care. A burgeoning number of diagnostic, predictive, prognostic, and monitoring biomarkers are continuously being explored to improve clinical decision making in neuro-oncology. These advancements describe the increasing incorporation of artificial intelligence (AI) algorithms, including the use of radiomics. However, the broad applicability and clinical translation of AI are restricted by concerns about generalisability, reproducibility, scalability, and validation. This Policy Review intends to serve as the leading resource of recommendations for the standardisation and good clinical practice of AI approaches in health care, particularly in neuro-oncology. To this end, we investigate the repeatability, reproducibility, and stability of AI in response assessment in neuro-oncology in studies on factors affecting such computational approaches, and in publicly available open-source data and computational software tools facilitating these goals. The pathway for standardisation and validation of these approaches is discussed with the view of trustworthy AI enabling the next generation of clinical trials. We conclude with an outlook on the future of AI-enabled neuro-oncology.
引用
- Bakas S, Vollmuth P, Galldiks N, et al. Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 2: recommendations for standardisation, validation, and good clinical practice. Lancet Oncol. 2024. PMID: 39481415. doi:10.1016/S1470-2045(24)00315-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。